hero image
Katharina Busl - University of Florida. Gainesville, FL, US

Katharina Busl Katharina Busl

M.D./Associate Professor | University of Florida

Gainesville, FL, UNITED STATES

Dr. Katharina Busl is an associate professor of neurology and neurosurgery.


Dr. Katharina Busl is the chief of the Division of Neurocritical Care, director of UF Health Shands Neurointensive Care Unit and the associate program director for the Neurocritical Care Fellowship. Her research centers around care innovations and quality of care in neurocritical care. Katharina's specific interests include treatment of headache in the NeuroICU, medical complications of neurocritical disease, neurogenic bladder and infections of the brain.

Areas of Expertise (4)

Subarachnoid Hemorrhage

Brain Death

Neurocritical Care

Acute Brain Injury


Articles (3)

Role of Dexmedetomidine in Aneurysmal Subarachnoid Hemorrhage: A Comprehensive Scoping Review

Journal of Neurosurgical Anesthesiology

Katharina M. Busl, et al.


Dexmedetomidine has been widely used for anesthesia, pain control, and intensive care unit sedation. Subarachnoid hemorrhage is a complex disease that is divided into 2 phases: early brain injury and delayed cerebral ischemia. Dexmedetomidine has been shown to have an effect on these Subarachnoid hemorrhage-related pathologic processes.

view more

Pregabalin for Recurrent Seizures in Critical Illness: A Promising Adjunctive Therapy, Especially for cyclic Seizures

Neurocritical Care

Katharina M. Busl, et al.


Pregabalin is an effective adjunctive treatment for focal epilepsy and acts by binding to the alpha2-delta subunit of voltage-gated calcium channels to reduce excitatory neurotransmitter release. Pregabalin has been shown to increase spreading depolarization threshold; hence, we hypothesized that the magnitude of antiseizure effect from pregabalin is more pronounced in patients with cyclic versus noncyclic seizures in a critically ill cohort with recurrent seizures.

view more

Early vigabatrin augmenting GABA-ergic pathways in post-anoxic status epilepticus (VIGAB-STAT) phase IIa clinical trial study protocol

Neurological Research and Practice

Katharina M. Busl, et al.


Nearly one in three unconscious cardiac arrest survivors experience post-anoxic status epilepticus. Historically, post-anoxic status epilepticus has been deemed untreatable resulting in its exclusion from status epilepticus clinical trials. However, emerging reports of survivors achieving functional independence following early and aggressive treatment of post-anoxic status epilepticus challenged this widespread therapeutic nihilism.

view more





Katharina Busl loading image